NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 597.85M
Enterprise Value 350.87M
Trailing P/E N/A
Forward P/E 1-1.43
PEG Ratio (5 yr expected) 1-0.01
Price/Sales (ttm)11.42
Price/Book (mrq)3.27
Enterprise Value/Revenue 35.94
Enterprise Value/EBITDA 6-0.63

Trading Information

Stock Price History

Beta (5Y Monthly) 2.50
52-Week Change 3-71.13%
S&P500 52-Week Change 35.67%
52 Week High 32.7700
52 Week Low 30.4850
50-Day Moving Average 30.7835
200-Day Moving Average 30.9509

Share Statistics

Avg Vol (3 month) 37.02M
Avg Vol (10 day) 33.19M
Shares Outstanding 5142.96M
Float 99.4M
% Held by Insiders 11.23%
% Held by Institutions 143.41%
Shares Short (Jun. 14, 2020) 46.46M
Short Ratio (Jun. 14, 2020) 40.59
Short % of Float (Jun. 14, 2020) 44.55%
Short % of Shares Outstanding (Jun. 14, 2020) 44.52%
Shares Short (prior month May 14, 2020) 42.96M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 210:1
Last Split Date 3Jun. 25, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-938.87%

Management Effectiveness

Return on Assets (ttm)-69.34%
Return on Equity (ttm)-214.46%

Income Statement

Revenue (ttm)8.57M
Revenue Per Share (ttm)0.11
Quarterly Revenue Growth (yoy)-53.70%
Gross Profit (ttm)-17M
EBITDA -80.06M
Net Income Avi to Common (ttm)-85.81M
Diluted EPS (ttm)-1.0640
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)27.11M
Total Cash Per Share (mrq)0.27
Total Debt (mrq)9M
Total Debt/Equity (mrq)45.18
Current Ratio (mrq)3.19
Book Value Per Share (mrq)0.21

Cash Flow Statement

Operating Cash Flow (ttm)-79.38M
Levered Free Cash Flow (ttm)-50.32M